Lymphangiogenesis, myeloid cells and inflammation

Expert Review of Clinical Immunology

Volumn 4, Issue 5, 2008, Pages 599-613

  Xing, Lianping ^a   Ji, Rui Cheng ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b OITA UNIVERSITY   (Japan)

Author keywords

Arthritis; Inflammation; Lymph node; Lymphatic drainage; Lymphatic vessel; Macrophage; Myeloid cell

Indexed keywords

FIBROBLAST GROWTH FACTOR 1; LYMPHATIC VASCULAR ENDOTHELIAL HYALURONAN RECEPTOR 1; MARKER; PLATELET DERIVED GROWTH FACTOR; PODOPLANIN; PROSPERO RELATED HOMEOBOX 1; SOMATOMEDIN; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ARTHRITIS; BONE MARROW CELL; DENDRITIC CELL; ENDOTHELIUM CELL; HUMAN; IMMUNOSURVEILLANCE; INFLAMMATION; KERATITIS; KIDNEY GRAFT REJECTION; LYMPHANGIOGENESIS; LYMPHATIC DRAINAGE; LYMPHATIC SYSTEM; LYMPHEDEMA; MACROPHAGE; METASTASIS; MOUSE; NONHUMAN; OSTEOCLAST; RESPIRATORY TRACT INFLAMMATION; REVIEW; WOUND HEALING;

EID: 69449085032     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.4.5.599     Document Type: Review

References (137)

1. Gerli R, Solito R, Weber E, Agliano M. Specific adhesion molecules bind anchoring filaments and endothelial cells in human skin initial lymphatics. Lymphology 33(4), 148-157 (2000).
2. Witte MH, Bernas MJ, Martin CP, Witte CL. Lymphangiogenesis and lymphangiodysplasia: from molecular to clinical lymphology. Microsc. Res. Tech. 55(2), 122-145 (2001).
3. Oliver G, Detmar M. The rediscovery of the lymphatic system: old and new insights into the development and biological function of the lymphatic vasculature. Genes Dev. 16(7), 773-783 (2002).
4. Acheson ED. Lymphatics and the gut. Br. Med. J. 1(5390), 1062 (1964).
5. Podgrabinska S, Braun P, Velasco P et al. Molecular characterization of lymphatic endothelial cells. Proc. Natl Acad. Sci. USA 99(25), 16069-16074 (2002).
6. Kriehuber E, Breiteneder-Geleff S, Groeger M et al. Isolation and characterization of dermal lymphatic and blood endothelial cells reveal stable and functionally specialized cell lineages. J. Exp. Med. 194(6), 797-808 (2001).
7. Makinen T, Veikkola T, Mustjoki S et al. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J. 20(17), 4762-4773 (2001).
8. Hirakawa S, Hong Y-K, Harvey N et al. Identification of vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endothelial cells. Am. J. Pathol. 162(2), 575-586 (2003).
9. Gale NW, Prevo R, Espinosa J et al. Normal lymphatic development and function in mice deficient for the lymphatic hyaluronan receptor LYVE-1. Mol. Cell. Biol. 27(2), 595-604 (2007).
10. Cho CH, Koh YJ, Han J et al. Angiogenic role of LYVE-1-positive macrophages in adipose tissue. Circ. Res. 100(4), e47-e57 (2007).
11. Wigle JT, Harvey N, Detmar M et al. An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. EMBO J. 21(7), 1505-1513 (2002). (Pubitemid 34614607)
12. Harvey NL, Srinivasan RS, Dillard ME et al. Lymphatic vascular defects promoted by Prox1 haploinsufficiency cause adult-onset obesity. Nat. Genet. 37(10), 1072-1081 (2005).
13. Ramirez MI, Millien G, Hinds A et al. T1?, a lung type I cell differentiation gene, is required for normal lung cell proliferation and alveolus formation at birth. Dev. Biol. 256(1), 62-73 (2003).
14. Schacht V, Ramirez MI, Hong YK et al. T1?/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J. 22(14), 3546-3556 (2003).
15. Mahtab EA, Wijffels MC, Van Den Akker NM et al. Cardiac malformations and myocardial abnormalities in podoplanin knockout mouse embryos: correlation with abnormal epicardial development. Dev. Dyn. 237(3), 847-857 (2008).
16. Dumont DJ, Jussila L, Taipale J et al. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 282(5390), 946-949 (1998).
17. Kukk E, Lymboussaki A, Taira S et al. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 122(12), 3829-3837 (1996).
18. Kaipainen A, Korhonen J, Mustonen T et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc. Natl Acad. Sci. USA 92(8), 3566-3570 (1995).
19. Makinen T, Jussila L, Veikkola T et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat. Med. 7(2), 199-205 (2001).
20. Kawai Y, Hosaka K, Kaidoh M et al. Heterogeneity in immunohistochemical, genomic, and biological properties of human lymphatic endothelial cells between initial and collecting lymph vessels. Lymphat. Res. Biol. 6(1), 15-27 (2008).
21. Maruyama K, II M, Cursiefen C et al. Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J. Clin. Invest. 115(9), 2363-2372 (2005).
22. Sironi M, Conti A, Bernasconi S et al. Generation and characterization of a mouse lymphatic endothelial cell line. Cell Tissue Res. 325(1), 91-100 (2006).
23. Hamada K, Oike Y, Takakura N et al. VEGF-C signaling pathways through VEGFR-2 and VEGFR-3 in vasculoangiogenesis and hematopoiesis. Blood 96(12), 3793-3800 (2000).
24. Mellor RH, Brice G, Stanton AW et al. Mutations in FOXC2 are strongly associated with primary valve failure in veins of the lower limb. Circulation 115(14), 1912-1920 (2007).
25. Murfee WL, Rappleye JW, Ceballos M, Schmid-Schonbein GW. Discontinuous expression of endothelial cell adhesion molecules along initial lymphatic vessels in mesentery: the primary valve structure. Lymphat. Res. Biol. 5(2), 81-89 (2007).
26. Cao R, Eriksson A, Kubo H et al. Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability. Circ. Res. 94(5), 664-670 (2004).
27. Brown P. Lymphatic system: unlocking the drains. Nature 436(7050), 456-458 (2005).
28. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature 438(7070), 946-953 (2005).
29. Joukov V, Pajusola K, Kaipainen A et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 15(7), 1751 (1996).
30. Karkkainen MJ, Haiko P, Sainio K et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat. Immunol. 5(1), 74-80 (2004).
31. Lee J, Gray A, Yuan J et al. Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc. Natl Acad. Sci. USA 93(5), 1988-1992 (1996).
32. Cao R, Bjorndahl MA, Religa P et al. PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell 6(4), 333-345 (2004).
33. Wirzenius M, Tammela T, Uutela M et al. Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting. J. Exp. Med. 204(6), 1431-1440 (2007).
34. Vincent L, Rafii S. Vascular frontiers without borders: multifaceted roles of platelet-derived growth factor (PDGF) in supporting postnatal angiogenesis and lymphangiogenesis. Cancer Cell. 6(4), 307-309 (2004).
35. Kubo H, Cao R, Brakenhielm E et al. Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. Proc. Natl Acad. Sci. USA 99(13), 8868-8873 (2002).
36. Bjorndahl M, Cao R, Nissen LJ et al. Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. Proc. Natl Acad. Sci. USA 102(43), 15593-15598 (2005).
37. Engeset A, Tjotta E. Lymphatic pathways from the tail in rats and mice. Cancer Res. 20, 613-617 (1960).
38. Kobayashi H, Kawamoto S, Brechbiel MW et al. Detection of lymph node involvement in hematologic malignancies using micromagnetic resonance lymphangiography with a gadolinumlabeled dendrimer nanoparticle. Neoplasia 7(11), 984-991 (2005).
39. Kobayashi H, Kawamoto S, Star RA et al. Micro-magnetic resonance lymphangiography in mice using a novel dendrimer-based magnetic resonance imaging contrast agent. Cancer Res. 63(2), 271-276 (2003).
40. Kobayashi H, Kawamoto S, Sakai Y et al. Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent. J. Natl Cancer Inst. 96(9), 703-708 (2004).
41. Leu AJ, Berk DA, Yuan F, Jain RK. Flow velocity in the superficial lymphatic network of the mouse tail. Am. J. Physiol. 267(4 Pt 2), H1507-H1513 (1994).
42. Kim S, Lim YT, Soltesz EG et al. Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat. Biotechnol. 22(1), 93-97 (2004).
43. Fox IJ, Wood EH. Indocyanine green: physical and physiologic properties. Proc. Staff Meet. Mayo Clin. 35, 732-744 (1960).
44. Sharma R, Wang W, Rasmussen JC et al. Quantitative imaging of lymph function. Am. J. Physiol. Heart Circ. Physiol. 292(6), H3109-H3118 (2007).
45. Sevick-Muraca EM, Sharma R, Rasmussen JC et al. Imaging of lymph flow in breast cancer patients after microdose administration of a near-infrared fluorophore: feasibility study. Radiology 246(3), 734-741 (2008).
46. Kwon S, Sevick-Muraca EM. Noninvasive quantitative imaging of lymph function in mice. Lymphat. Res. Biol. 5(4), 219-231 (2007).
47. Kerjaschki D, Regele HM, Moosberger I et al. Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphocytic infiltrates. J. Am. Soc. Nephrol. 15(3), 603-612 (2004).
48. Baluk P, Tammela T, Ator E et al. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J. Clin. Invest. 115(2), 247-257 (2005).
49. Kaiserling E. Newly-formed lymph nodes in the submucosa in chronic inflammatory bowel disease. Lymphology 34(1), 22-29 (2001).
50. Middel P, Raddatz D, Gunawan B, Haller F, Radzun HJ. Increased number of mature dendritic cells in Crohn's disease: evidence for a chemokine mediated retention mechanism. Gut 55(2), 220-227 (2006).
51. Paavonen K, Mandelin J, Partanen T et al. Vascular endothelial growth factors C and D and their VEGFR-2 and 3 receptors in blood and lymphatic vessels in healthy and arthritic synovium. J. Rheumatol. 29(1), 39-45 (2002).
52. Akashi K, Traver D, Miyamoto T, Weissman IL. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 404(6774), 193-197 (2000).
53. Xing L, Schwarz E. Circulating osteoclast precursors: a mechanism and a marker of erosive arthritis. Curr. Rheumatol. Rev. 1, 21-28 (2005).
54. Schmidt-Weber CB, Pohlers D, Siegling A et al. Cytokine gene activation in synovial membrane, regional lymph nodes, and spleen during the course of rat adjuvant arthritis. Cell. Immunol. 195(1), 53-65 (1999).
55. Zhang Q, Lu Y, Proulx S et al. Increased lymphangiogenesis in joints of mice with inflammatory arthritis. Arthritis Res. Ther. 9(6), R118 (2007).
56. Kerjaschki D, Huttary N, Raab I et al. Lymphatic endothelial progenitor cells contribute to de novo lymphangiogenesis in human renal transplants. Nat. Med. 12(2), 230-234 (2006).
57. Maruyama K, Asai J, II M et al. Decreased macrophage number and activation lead to reduced lymphatic vessel formation and contribute to impaired diabetic wound healing. Am. J. Pathol. 170(4), 1178-1191 (2007).
58. Oliver G, Alitalo K. The lymphatic vasculature: recent progress and paradigms. Annu. Rev. Cell. Dev. Biol. 21, 457-483 (2005).
59. Srinivasan RS, Dillard ME, Lagutin OV et al. Lineage tracing demonstrates the venous origin of the mammalian lymphatic vasculature. Genes Dev. 21(19), 2422-2432 (2007).
60. Grunewald M, Avraham I, Dor Y et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 124(1), 175-189 (2006).
61. Trombetta ES, Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu. Rev. Immunol. 23, 975-1028 (2005).
62. Dumitriu IE, Bianchi ME, Bacci M, Manfredi AA, Rovere-Querini P. The secretion of HMGB1 is required for the migration of maturing dendritic cells. J. Leukoc. Biol. 81(1), 84-91 (2007).
63. la Sala A, Ferrari D, Di Virgilio F et al. Alerting and tuning the immune response by extracellular nucleotides. J. Leukoc. Biol. 73(3), 339-343 (2003).
64. Di Virgilio F, Chiozzi P, Ferrari D et al. Nucleotide receptors: an emerging family of regulatory molecules in blood cells. Blood 97(3), 587-600 (2001).
65. Randolph GJ, Angeli V, Swartz MA. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat. Rev. Immunol. 5(8), 617-628 (2005).
66. Pugh CW, MacPherson GG, Steer HW. Characterization of nonlymphoid cells derived from rat peripheral lymph. J. Exp. Med. 157(6), 1758-1779 (1983).
67. MacPherson GG, Jenkins CD, Stein MJ, Edwards C. Endotoxin-mediated dendritic cell release from the intestine. Characterization of released dendritic cells and TNF dependence. J. Immunol. 154(3), 1317-1322 (1995).
68. Forster R, Schubel A, Breitfeld D et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99(1), 23-33 (1999).
69. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401(6754), 708-712 (1999).
70. Jang MH, Sougawa N, Tanaka T et al. CCR7 is critically important for migration of dendritic cells in intestinal lamina propria to mesenteric lymph nodes. J. Immunol. 176(2), 803-810 (2006).
71. Mathis D, Benoist C. Back to central tolerance. Immunity 20(5), 509-516 (2004).
72. Jakubzick C, Tacke F, Llodra J, van Rooijen N, Randolph GJ. Modulation of dendritic cell trafficking to and from the airways. J. Immunol. 176(6), 3578-3584 (2006).
73. Anderson DM, Maraskovsky E, Billingsley WL et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390, 175-179 (1997).
74. Wong BR, Rho J, Arron J et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272, 25190-25194 (1997).
75. Zhang Q, Guo R, Lu Y et al. VEGF-C, a lymphatic growth factor, is a RANKL target gene in osteoclasts that enhances osteoclastic bone resorption through an autocrine mechanism. J. Biol. Chem. 283(19), 13491-13499 (2008).
76. Yao Z, Li P, Zhang Q et al. Tumor necrosis factor-? increases circulating osteoclast precursor numbers by promoting their proliferation and differentiation in the bone marrow through up-regulation of c-Fms expression. J. Biol. Chem. 281(17), 11846-11855 (2006).
77. Jacquin C, Gran DE, Lee SK, Lorenzo JA, Aguila HL. Identification of multiple osteoclast precursor populations in murine bone marrow. J. Bone Miner. Res. 21(1), 67-77 (2006).
78. Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol. Med. 12(1), 17-25 (2006).
79. Asagiri M, Takayanagi H. The molecular understanding of osteoclast differentiation. Bone 40(2), 251-264 (2007).
80. Boyce BF, Yamashita T, Yao Z et al. Roles for NF-?B and c-Fos in osteoclasts. J. Bone Miner. Metab. 23(Suppl.), 11-15 (2005).
81. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat. Rev. Immunol. 7(4), 292-304 (2007).
82. Tanaka Y, Abe M, Hiasa M et al. Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin. Clin. Cancer Res. 13(3), 816-823 (2007).
83. Kubota K, Sakikawa C, Katsumata M, Nakamura T, Wakabayashi K. Plateletderived growth factor BB secreted from osteoclasts acts as an osteoblastogenesis inhibitory factor. J. Bone Miner. Res. 17(2), 257-265 (2002).
84. Boyce BF, Schwarz EM, Xing L. Osteoclast precursors: cytokinestimulated immunomodulators of inflammatory bone disease. Curr. Opin. Rheumatol. 18(4), 427-432 (2006).
85. Xing L, Schwarz EM, Boyce BF. Osteoclast precursors, RANKL/RANK, and immunology. Immunol. Rev. 208, 19-29 (2005).
86. Pettit AR, Walsh NC, Manning C, Goldring SR, Gravallese EM. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis. Rheumatology 45(9), 1068-1076 (2006).
87. Gonzalez-Alvaro I, Ortiz AM, Tomero EG et al. Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists. Ann. Rheum. Dis. 66(12), 1675-1678 (2007).
88. Dougall WC, Chaisson M. The RANK/RANKL/OPG triad in cancer-induced bone diseases. Cancer Metastasis Rev. 25(4), 541-549 (2006).
89. Chen G, Sircar K, Aprikian A et al. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 107(2), 289-298 (2006).
90. Randolph GJ, Ochando J, Partida-Sanchez S. Migration of dendritic cell subsets and their precursors. Annu. Rev. Immunol. 26, 293-316 (2008).
91. Massberg S, Schaerli P, Knezevic-Maramica I et al. Immunosurveillance by hematopoietic progenitor cells trafficking through blood, lymph, and peripheral tissues. Cell 131(5), 994-1008 (2007).
92. Angeli V, Ginhoux F, Llodra J et al. B cell-driven lymphangiogenesis in inflamed lymph nodes enhances dendritic cell mobilization. Immunity 24(2), 203-215 (2006).
93. Halin C, Tobler NE, Vigl B, Brown LF, Detmar M. VEGF-A produced by chronically inflamed tissue induces lymphangiogenesis in draining lymph nodes. Blood 110(9), 3158-3167 (2007).
94. Proulx ST, Kwok E, You Z et al. MRI and quantification of draining lymph node function in inflammatory arthritis. Ann. NY Acad. Sci. 1117, 106-123 (2007).
95. Motulsky AG, Weinberg S, Saphir O, Rosenberg E. Lymph nodes in rheumatoid arthritis. AMA Arch. Intern. Med. 90(5), 660-676 (1952).
96. Cambiaggi G. [Lymph nodes in rheumatoid arthritis; lymph node hyperplasia of Symmers' type in a case of Still's disease.]. Progr. Med. (Napoli) 10(16), 488-491 (1954).
97. Olszewski WL, Pazdur J, Kubasiewicz E et al. Lymph draining from foot joints in rheumatoid arthritis provides insight into local cytokine and chemokine production and transport to lymph nodes. Arthritis Rheum. 44(3), 541-549 (2001).
98. Huh YM, Kim S, Suh JS et al. The role of popliteal lymph nodes in differentiating rheumatoid arthritis from osteoarthritis by using CE 3D FSPGR MR imaging: relationship of the inflamed synovial volume. Korean J. Radiol. 6(2), 117-124 (2005).
99. Ji RC, Miura M, Qu P, Kato S. Expression of VEGFR-3 and 5́-nase in regenerating lymphatic vessels of the cutaneous wound healing. Microsc. Res. Tech. 64(3), 279-286 (2004).
100. Qu P, Ji RC, Kato S. Expression of CCL21 and 5́-nase on pancreatic lymphatics in nonobese diabetic mice. Pancreas 31(2), 148-155 (2005).
101. Qi H, Egen JG, Huang AY, Germain RN. Extrafollicular activation of lymph node B cells by antigen-bearing dendritic cells. Science 312(5780), 1672-1676 (2006).
102. Regina M, Zimmerman R, Malik G, Gausas R. Lymphangiogenesis concurrent with haemangiogenesis in the human cornea. Clin. Experiment Ophthalmol. 35(6), 541-544 (2007).
103. Cursiefen C, Maruyama K, Jackson DG, Streilein JW, Kruse FE. Time course of angiogenesis and lymphangiogenesis after brief corneal inflammation. Cornea 25(4), 443-447 (2006).
104. Hamrah P, Chen L, Zhang Q, Dana MR. Novel expression of vascular endothelial growth factor receptor (VEGFR)-3 and VEGF-C on corneal dendritic cells. Am. J. Pathol. 163(1), 57-68 (2003).
105. Cursiefen C, Chen L, Borges LP et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J. Clin. Invest. 113(7), 1040-1050 (2004).
106. Hamrah P, Chen L, Cursiefen C et al. Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) on monocytic bone marrow-derived cells in the conjunctiva. Exp. Eye Res. 79(4), 553-561 (2004).
107. Chen L, Hamrah P, Cursiefen C et al. Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. Nat. Med. 10(8), 813-815 (2004).
108. Cursiefen C, Rummelt C, Junemann A et al. Absence of blood and lymphatic vessels in the developing human cornea. Cornea 25(6), 722-726 (2006).
109. Tugues S, Morales-Ruiz M, Fernandez-Varo G et al. Microarray analysis of endothelial differentially expressed genes in liver of cirrhotic rats. Gastroenterology 129(5), 1686-1695 (2005).
110. Hong YK, Shin JW, Detmar M. Development of the lymphatic vascular system: a mystery unravels. Dev. Dyn. 231(3), 462-473 (2004).
111. Kunstfeld R, Hirakawa S, Hong YK et al. Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia. Blood 104(4), 1048-1057 (2004).
112. Kajiya K, Hirakawa S, Detmar M. Vascular endothelial growth factor-A mediates ultraviolet B-induced impairment of lymphatic vessel function. Am. J. Pathol. 169(4), 1496-1503 (2006).
113. Kajiya K, Detmar M. An important role of lymphatic vessels in the control of UVB-induced edema formation and inflammation. J. Invest. Dermatol. 126(4), 919-921 (2006).
114. Wetzler C, Kampfer H, Stallmeyer B, Pfeilschifter J, Frank S. Large and sustained induction of chemokines during impaired wound healing in the genetically diabetic mouse: prolonged persistence of neutrophils and macrophages during the late phase of repair. J. Invest. Dermatol. 115(2), 245-253 (2000).
115. Saaristo A, Tammela T, Farkkila A et al. Vascular endothelial growth factor-C accelerates diabetic wound healing. Am. J. Pathol. 169(3), 1080-1087 (2006).
116. Ji RC. Characteristics of lymphatic endothelial cells in physiological and pathological conditions. Histol. Histopathol. 20(1), 155-175 (2005).
117. Stuht S, Gwinner W, Franz I et al. Lymphatic neoangiogenesis in human renal allografts: results from sequential protocol biopsies. Am. J. Transplant. 7(2), 377-384 (2007).
118. Huber S, Bruns CJ, Schmid G et al. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney Int. 71(8), 771-777 (2007).
119. Verhaeghe C, Tabruyn SP, Oury C, Bours V, Griffioen AW. Intrinsic proangiogenic status of cystic fibrosis airway epithelial cells. Biochem. Biophys. Res. Commun. 356(3), 745-749 (2007).
120. Matsui K, Nagy-Bojarsky K, Laakkonen P et al. Lymphatic microvessels in the rat remnant kidney model of renal fibrosis: aminopeptidase p and podoplanin are discriminatory markers for endothelial cells of blood and lymphatic vessels. J. Am. Soc. Nephrol. 14(8), 1981-1989 (2003).
121. Fogt F, Zimmerman RL, Daly T, Gausas RE. Observation of lymphatic vessels in orbital fat of patients with inflammatory conditions: a form fruste of lymphangiogenesis? Int. J. Mol. Med. 13(5), 681-683 (2004).
122. Aurora AB, Baluk P, Zhang D et al. Immune complex-dependent remodeling of the airway vasculature in response to a chronic bacterial infection. J. Immunol. 175(10), 6319-6326 (2005).
123. Xu H, Edwards J, Banerji S et al. Distribution of lymphatic vessels in normal and arthritic human synovial tissues. Ann. Rheum. Dis. 62(12), 1227-1229 (2003).
124. Cha HS, Bae EK, Koh JH et al. Tumor necrosis factor-? induces vascular endothelial growth factor-C expression in rheumatoid synoviocytes. J. Rheumatol. 34(1), 16-19 (2007).
125. Zhang Q, Lu Y, Proulx ST et al. Increased lymphangiogenesis in joints of mice with inflammatory arthritis. Arthritis Res. Ther. 9(6), R118 (2007).
126. Tsai PW, Shiah SG, Lin MT, Wu CW, Kuo ML. Up-regulation of vascular endothelial growth factor C in breast cancer cells by heregulin-α 1. A critical role of p38/nuclear factor-κ B signaling pathway. J. Biol. Chem. 278(8), 5750-5759 (2003).
127. Saban MR, Memet S, Jackson DG et al. Visualization of lymphatic vessels through NF-κB activity. Blood 104(10), 3228-3230 (2004).
128. Xing L, Bushnell TP, Carlson L et al. NF-?B p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. J. Bone Miner. Res. 17(7), 1200-1210 (2002).
129. Burkly L, Hession C, Ogata L et al. Expression of relB is required for the development of thymic medulla and dendritic cells. Nature 373(6514), 531-536 (1995).
130. Weih F, Carrasco D, Durham SK et al. Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-κ B/Rel family. Cell 80(2), 331-340 (1995).
131. Carrasco D, Cheng J, Lewin A et al. Multiple hemopoietic defects and lymphoid hyperplasia in mice lacking the transcriptional activation domain of the c-Rel protein. J. Exp. Med. 187(7), 973-984 (1998).
132. Polzer K, Baeten D, Soleiman A et al. TNF blockade increases lymphangiogenesis in murine and human arthritic joints. Ann. Rheum. Dis. (2008) (Epub ahead of print).
133. Furtado GC, Marinkovic T, Martin AP et al. Lymphotoxin ? receptor signaling is required for inflammatory lymphangiogenesis in the thyroid. Proc. Natl Acad. Sci. USA 104(12), 5026-5031 (2007).
134. Szczesny G, Olszewski WL, Gorecki A. Lymphoscintigraphic monitoring of the lower limb lymphatic system response to bone fracture and healing. Lymphat. Res. Biol. 3(3), 137-145 (2005).
135. Edwards JR, Williams K, Kindblom LG et al. Lymphatics and bone. Hum. Pathol. 39(1), 49-55 (2008).
136. Jell G, Kerjaschki D, Revell P, Al-Saffar N. Lymphangiogenesis in the bone- implant interface of orthopedic implants: importance and consequence. J. Biomed. Mater. Res A. 77(1), 119-127 (2006).
137. Edwards J, Schulze E, Sabokbar A et al. Absence of lymphatics at the bone-implant interface: implications for periprosthetic osteolysis. Acta Orthop. 79(2), 289-294 (2008).